Does PRP work for joint soreness?

Why can people improve when a study is mixed?

Joint aches can change from day to day without a new injury. Rest, exercise, and care after a procedure may also help you.

Some tests found similar relief over time from PRP, marrow, and simpler shots. People still may have felt better and moved more easily in daily life after care.

The tests couldn't tell whether the procedure, rest, exercise, or follow-up eased soreness. Your result can't predict what another person will feel after the same procedure.

What have comparisons of PRP and marrow found?

Several comparisons found little difference between PRP and marrow care. Other reviews didn't find a clear reason to favor marrow.

Marrow requires a needle into your pelvis as well. You can weigh that extra procedure against an uncertain result.

After medical providers examine your joint, QC Kinetix may offer regenerative treatments for soreness using material collected from blood or marrow. Regenerative doesn't mean that worn tissue has been shown to return.

Can these treatments rebuild my joint?

Research hasn't shown these procedures rebuilding a worn joint. Joint images haven't shown clear repair or new cartilage.

Less soreness and a rebuilt joint aren't the same result. You may feel better while your X-ray stays unchanged.

The plain answer about proven repair is no. Claims about rebuilding deserve a careful question before you pay.

Sources

1. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 HA patients) found significantly better post-injection WOMAC, VAS and subjective IKDC scores for BOTH PRP and BMAC compared with hyaluronic acid - and NO significant difference between PRP and BMAC on any outcome score. This is the clearest published statement that the two most-marketed orthobiologics perform the same as each other in the knee.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

3. A randomized trial allocated 175 patients with KL II-IV knee OA to BMAC (n=111), PRP (n=34) or hyaluronic acid (n=30) and followed them for 12 months. All three produced significant improvement from baseline in WOMAC, KOOS and IKDC with no serious side effects; BMAC showed significantly better clinical improvement than PRP and HA on most scores, and PRP scored higher than HA without reaching statistical significance. Note the unequal, non-blinded design - this is the strongest direct BMAC-versus-PRP randomized comparison available, and it is not a strong design.

   Dulic O, et al. — Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.. Medicina (Kaunas), 2021. DOI: 10.3390/medicina57111193.

4. In a within-patient placebo-controlled trial, 25 people with BILATERAL knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline in the other, acting as their own controls. Pain scores fell significantly from baseline in BOTH knees at 1 week, 3 months and 6 months, and the relief - described by the authors as dramatic - did not differ significantly between the BMAC knee and the saline knee.

   Shapiro SA, et al. — A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.. American Journal of Sports Medicine, 2017. DOI: 10.1177/0363546516662455.

5. A phase III double-blind placebo-controlled trial of a SINGLE injection of culture-expanded autologous adipose-derived MSCs in 261 patients with KL grade 3 knee OA found significantly better VAS pain (25.2 vs 15.5 mm improvement; P=.004) and total WOMAC (21.7 vs 14.3; P=.002) at 6 months versus placebo, with no serious treatment-related adverse events - but MRI showed NO significant difference in cartilage-defect change between groups. Culture-expanded cells of this kind are a drug in the United States and are not available outside a trial.

   Kim KI, et al. — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.. American Journal of Sports Medicine, 2023. DOI: 10.1177/03635465231179223.

6. The ADIPOA2 phase 2b trial randomised 135 patients with mild-to-moderate knee OA to low-dose (2 million) or high-dose (10 million) culture-expanded autologous adipose-derived stromal cells or saline placebo. At 6 months 47.3% of ADSC patients were OARSI/OMERACT strict responders versus 54.8% on placebo (relative risk 0.86; P=.46), and no secondary outcome differed significantly. A single injection of expanded adipose stromal cells did NOT improve pain or function versus saline.

   Pers YM, et al. — Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial.. Annals of the Rheumatic Diseases, 2025. DOI: 10.1016/j.ard.2025.07.026.

7. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

8. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

9. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

10. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

    Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

11. The companion ESSKA-ORBIT consensus on cell-based therapy (77 experts, 22 countries, 27 statements) found only 5 of 27 statements reached recommendation level A or B; 22 were rated C or D. It concluded that cell-based therapy shows clinical benefit in pain and function up to 12 months for KL grades 1-3 with some benefit in selected KL 4, but that because of limited high-quality studies and NO clear superiority over other injectables it should be considered a SECOND-LINE option, after other non-operative treatment fails.

    de Girolamo L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.. Knee Surgery, Sports Traumatology, Arthroscopy, 2025. DOI: 10.1002/ksa.70001.

12. A multicenter single-blind RCT randomised 200 patients 1:1:1 to a single injection of saline, hyaluronic acid or amniotic suspension allograft. ASA produced significant KOOS and VAS improvements maintained through 12 months with a 63.2% OMERACT-OARSI responder rate, no radiographic differences, and no concerning immunoglobulin or anti-HLA responses. Adverse events with ASA were comparable to HA, while NO treatment-emergent adverse events were reported in the saline group.

    Gomoll AH, et al. — Safety and Efficacy of an Amniotic Suspension Allograft Injection Over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2021.02.044.